Author

S. F. Cai

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pathology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:clustering· 1 Research Focus:differential expression· 1

Frequent Co-Authors

R. L. Bowman· 4 shared W. Xiao· 4 shared A. D. Goldberg· 3 shared M. R. Waarts· 3 shared R. L. Levine· 3 shared T. Mishra· 3 shared A. Dogan· 2 shared A. Dunbar· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPathology

R. L. Bowman

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia

T. T. Robinson, R. L. Bowman, S. Persaud, Y. Liu, Q. Gao, J. Zhang, X. Sun, L. A. Miles, S. F. Cai, A. Sciambi, A. Llanso, F. A. Christopher, A. D. Goldberg, A. Dogan, M. Roshal, , W. Xiao

The paper develops a single-cell MRD assay that detects residual leukemic clones with high sensitivity and reveals clonal architecture in AML.

bioRxiv · Sep 20, 2022 · PreprintPathology

Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation

R. L. Bowman, A. Dunbar, T. Mishra, W. Xiao, M. R. Waarts, I. Fernandez Maestre, S. E. Eisman, L. Cai, S. F. Cai, P. Sanchez Vela, S. Mowla, A. R. Martinez Benitez, Y. Park, I. S. Csete, A. Krishnan, , R. L. Levine

This study models clonal evolution and oncogenic dependency in hematopoietic transformation using reversible mutagenesis and allelic frameworks.

bioRxiv · May 18, 2022 · PreprintCancer Biology

Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms

A. Dunbar, R. L. Bowman, Y. Park, F. Izzo, R. M. Myers, A. Karzai, W. Jun Kim, I. Fernandez Maestre, M. R. Waarts, A. Nazir, W. Xiao, M. Brodsky, M. Farina, L. Cai, S. F. Cai, , R. L. Levine

This study shows that reversible activation of Jak2V617F in a mouse model demonstrates its essential role in myeloproliferative neoplasms and highlights the therapeutic potential of mutant-specific JAK2 inhibition.

bioRxiv · May 18, 2022 · PreprintCancer Biology

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 mutated acute myeloid leukemia

W. Xiao, A. Chan, M. R. Waarts, T. Mishra, Y. Liu, S. F. Cai, J. Yao, Q. Gao, R. L. Bowman, R. Koche, I. S. Csete, J. Baik, S. Yanis, C. Famulare, M. Patel, , R. Levine

This study identifies pDC-AML as a distinct AML subset with high RUNX1 mutations and pDC transcriptional features, suggesting CD123 targeting as a therapeutic strategy.

Blood · Mar 11, 2021Peer-reviewedPathology

Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition

S. F. Cai, S. H. Chu, A. D. Goldberg, S. Parvin, R. P. Koche, J. L. Glass, E. M. Stein, M. S. Tallman, F. Sen, C. Famulare, M. Cusan, C.-H. Huang, C.-W. Chen, L. Zou, K. B. Cordner, , S. A. Armstrong

This study shows that leukemia cell of origin affects apoptotic priming and sensitivity to LSD1 inhibitors, with Evi1 modulating p53 stability and activity.

bioRxiv · May 11, 2020Cancer Biology